Fig. 3From: Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancerPharmacodynamic effects of TAK-960 on relevant downstream effectors. Two sensitive (a, b) and two resistant (c, d) CRC cell lines were exposed to TAK-960 (0.01, 0.05, 0.1, 0.2, 0.5, 1.0 μM) or mock treated control for 8, 24, 48 h, and 72 h. N = 3Back to article page